[Multiple sclerosis and Epstein-Barr virus : new developments and perspectives].
Data from studies of twins and migrants with multiple sclerosis (MS) imply environmental factors in the development of MS. In this respect, increasing evidence indicates that Epstein-Barr virus (EBV) plays a unique role as an infectious risk factor for MS. A nearly 100% seroprevalence of antibodies to EBV in patients with MS, elevated EBV antibody titers years before clinical onset of the disease, and an increased risk for MS after symptomatic primary EBV infection (infectious mononucleosis) suggest an association of MS with a previous infection with EBV. However, the precise mechanisms through which EBV may contribute to MS are still unclear. Currently discussed potential mechanisms are outlined. The notion of a persisting (possibly immunological) change caused during the acute phase of primary EBV infection and subsequently leading to permanently elevated MS risk appears compatible with several aspects of the association found between MS and EBV.
Ruprecht
K
K
Institut für Virologie, Haus 47, Universitätsklinikum des Saarlandes, 66421, Homburg/Saar, Deutschland. klemens.ruprecht@uniklinikum-saarland.de
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000276:immunology*; D002648:Child; D019309:Epstein-Barr Virus Nuclear Antigens / Q000276:immunology; D004854:Herpesvirus 4, Human / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D007244:Infectious Mononucleosis / Q000453:epidemiology / Q000276:immunology*; D009103:Multiple Sclerosis / Q000453:epidemiology / Q000276:immunology*; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D012897:Slow Virus Diseases / Q000453:epidemiology / Q000276:immunology*; D014774:Virulence
D000914:Antibodies, Viral; D019309:Epstein-Barr Virus Nuclear Antigens
Arch Neurol. 2007 Jan;64(1):72-5
17210811
Acta Neurol Scand Suppl. 1997;169:8-15
9174635
Nat Immunol. 2002 Oct;3(10):940-3
12244309
J Immunol. 1999 Jan 1;162(1):129-35
9886378
Blood. 2006 Jul 1;108(1):11-8
16543467
Arch Neurol. 1980 Feb;37(2):94-6
6243930
JAMA. 2006 Dec 20;296(23):2832-8
17179460
JAMA. 2003 Jul 9;290(2):192-3; author reply 193
12851269
Neurology. 2004 Jun 22;62(12):2277-82
15210894
JAMA. 2004 Apr 21;291(15):1875-9
15100207
Lancet Neurol. 2005 Mar;4(3):195-202
15721830
Trends Immunol. 2003 Nov;24(11):584-8
14596882
JAMA. 2005 May 25;293(20):2496-500
15914750
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12877-82
14569025
Int MS J. 2006 May;13(2):52-7
16635422
Neurology. 2006 Dec 12;67(11):2063-5
17159123
Immunity. 2001 Oct;15(4):579-89
11672540
Arch Neurol. 2006 Jun;63(6):839-44
16606758
Lancet. 1981 Dec 5;2(8258):1290
6118702
J Neuroimmunol. 2006 Nov;180(1-2):185-92
17023054
Neuroepidemiology. 1992;11(4-6):299-303
1337948
JAMA. 2001 Dec 26;286(24):3083-8
11754673
J Epidemiol Community Health. 2004 Dec;58(12):1032-5
15547068
Rev Med Virol. 2006 Sep-Oct;16(5):297-310
16927411
Nat Immunol. 2001 Sep;2(9):802-9
11526390
Ann Neurol. 2006 Mar;59(3):499-503
16502434
Prog Neurobiol. 1995 Nov-Dec;47(4-5):425-48
8966212
Ann Neurol. 2007 Apr;61(4):288-99
17444504